Hormonal
Tirzepatide (5, 10, and 15 mg once weekly) produces significantly greater weight loss than both placebo and GLP-1 receptor agonists (semaglutide, dulaglutide) in adults with overweight or obesity.
If you have overweight or obesity, tirzepatide (administered once weekly) is a highly effective pharmacological option for weight loss, outperforming both placebo and existing GLP-1 medications like semaglutide. Expect significant weight reduction (up to ~12.5 kg with the highest dose) and a higher likelihood of achieving major weight loss milestones (5%, 10%, 15%). Be prepared for potential gastrointestinal side effects (nausea, diarrhea), which are common but often manageable and comparable to other drugs in this class. Consult a healthcare provider to determine if you are a candidate based on your BMI and health status.
Once-weekly doses (5, 10 and 15 mg) of tirzepatide were more efective than placebo and GLP-1 RAs. Also, the proportion of patients achieving categorical weight loss goals was higher in the tirzepatide groups than in others.
Why this rating
Meta-analysis of 6 RCTs with 6266 participants; GRADE assessment indicates high certainty for ≥15% weight loss and moderate-to-low for lower thresholds.
Source
Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP‐1 Receptor Agonists in Adults With Obesity or Overweight: A Meta‐Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration
Alhussain Khawaji et al. · Journal of Obesity · 2025
DOI 10.1155/jobe/3442754
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →